Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced multiple presentations at the upcoming Society of Gynecologic Oncology (SGO) 2025 Annual Meeting, scheduled for March 14-17 in Seattle. The presentations include updated clinical data from the Phase 2 DENALI trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC).

Key highlights include an oral presentation by Dr. Fiona Simpkins focusing on Cyclin E1 as a predictive biomarker of azenosertib benefit in PROC patients, scheduled for March 15. Additionally, a poster presentation by Dr. Joanna Guo will showcase preclinical data demonstrating synergistic antitumor effects of azenosertib when combined with microtubule inhibitor-based antibody drug conjugates (ADCs).

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer and other tumor types, has announced its participation in two major investor conferences.

The company will participate in:

• The TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside discussion scheduled for March 3, 2025, at 11:50 a.m. ET
• The Leerink Global Healthcare Conference in Miami, FL, with a fireside discussion scheduled for March 10, 2025, at 9:20 a.m. ET

Live webcasts and archived recordings of both events will be accessible through the 'Events & Presentations' tab on the Investors & Media section of Zentalis' website.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to one newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant includes options to purchase 35,000 shares of common stock at an exercise price of $1.68 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for individuals not previously employed by Zentalis.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has presented updated clinical data for azenosertib in treating Cyclin E1+ platinum-resistant ovarian cancer (PROC). The DENALI Part 1b study showed an Objective Response Rate (ORR) of approximately 35% in response-evaluable patients.

Key findings include a median duration of response of approximately 5.5 months, with patients continuing therapy. The safety profile remains well-characterized across over 350 patients treated at clinically active monotherapy doses, with no new safety concerns identified.

The company has aligned with FDA on the design of DENALI Part 2 study, expected to begin in 1H 2025, with topline data anticipated by year-end 2026. The study could potentially support accelerated approval, subject to FDA review. Notably, approximately 50% of PROC patients are Cyclin E1+, representing a substantial therapeutic and commercial opportunity.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced a strategic restructuring to focus on late-stage development of its WEE1 inhibitor, azenosertib. The company plans a workforce reduction of approximately 40% to be completed in Q2 2025, extending its cash runway into late 2027.

The restructuring aims to support the execution of the potentially registration-enabling DENALI Part 2 study, with data readout anticipated by the end of 2026. The company will host a virtual corporate event on January 29, 2025, to present updated azenosertib clinical data and provide development and regulatory updates, including plans for registration-intent studies.

Zentalis Pharmaceuticals (ZNTL) announced that the FDA has granted Fast Track Designation to azenosertib for treating Cyclin E1-positive patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC). This designation aims to expedite the development and review process for medicines addressing serious unmet medical needs.

The company published research in npj Precision Oncology demonstrating that high levels of Cyclin E1/CDK2 activation predict sensitivity to azenosertib. Zentalis will host a corporate webcast on January 29, 2025, to present comprehensive clinical data, including topline results from 102 patients in the Phase 2 DENALI study, final results from Phase 1b trial with 69 PROC patients, and data from 61 patients in the MAMMOTH trial. The event will also cover registration-intent study designs and regulatory updates.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to two newly hired employees on January 2, 2025. The grants include options to purchase 45,000 shares of common stock at an exercise price of $3.00 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options were granted under the company's 2022 Employment Inducement Incentive Award Plan, following Nasdaq Listing Rule 5635(c)(4). These 10-year term options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced two key executive appointments to support its focus on developing azenosertib for gynecological malignancies. Wendy Chang joins as Chief People Officer, bringing over 20 years of biopharma experience, including previous roles at Harpoon Therapeutics, IDbyDNA, and Gilead Sciences. Haibo Wang has been appointed as Chief Business Officer, contributing more than 15 years of biopharma business development experience, notably managing Harpoon Therapeutics' recent acquisition by Merck in March 2024. Wang previously held positions at Hummingbird Bioscience and Amgen, where he was involved in significant acquisitions and collaborations.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced equity awards granted by its Compensation Committee on December 2, 2024. The grants include non-qualified stock options for: 3,028,800 shares to Julie Eastland (new CEO and President), 712,650 shares to Dr. Ingmar Bruns (new Chief Medical Officer), and 753,660 shares to five new employees. The options, granted under the 2022 Inducement Plan, have an exercise price of $3.66 per share. Eastland's options vest monthly over four years, while other employees' options vest 25% after one year and the remaining 75% monthly over three years, subject to continued service.